Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C

Journal of Hepatology

Volumn 58, Issue 6, 2013, Pages 1096-1103

  Sanai, Faisal M ^a,b   Mousa, Dujana ^a   Al Mdani, Abdallah ^a   Al Shoail, Ghada ^a   Al Ashgar, Hamad ^c   Al Meshari, Khalid ^c   Al Qahtani, Ahmed ^b,c   Saadeh, Mayssa ^d   Bzeizi, Khalid I ^a   Aleid, Hassan ^c  

^a Prince Sultan Military Medical City   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER   (Saudi Arabia)

Author keywords

Acute rejection; Hepatitis C virus; Pegylated interferon; Renal transplant; Sustained virologic response; Treatment

Indexed keywords

CREATININE; CYCLOSPORIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; RIBAVIRIN; TACROLIMUS; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; ASCITES; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM PERFORATION; DUODENUM ULCER; DYSPNEA; FATIGUE; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER FIBROSIS; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RISK ASSESSMENT; SIDE EFFECT; SINGLE BLIND PROCEDURE; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; AGED; CLINICAL TRIAL; DRUG COMBINATION; HEPATITIS C, CHRONIC; MIDDLE AGED; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84877920711     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.02.004     Document Type: Article

References (24)

1. B.J.G. Pereira, T.L. Wright, C.H. Schmid, and A.S. Levey The impact of pretransplantation hepatitis C infection on the outcome of transplantation Transplantation 60 1995 799 805
2. A.H. Mitwalli, A. Alam, J. Al-Wakeel, K. Al Suwaida, N. Tarif, and T.A. Schaar Effects of chronic viral hepatitis on graft survival in Saudi renal transplant patients Nephron Clin Pract 102 2006 c72 c80
3. C. Legendre, V. Garrigue, C. Le Bihan, M.F. Mamzer-Bruneel, M.L. Chaix, and P. Landais Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients Transplantation 65 1998 667 670
4. T. Hanafusa, Y. Ichikawa, H. Kishikawa, M. Kyo, T. Fukunishi, and Y. Kokado Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years Transplantation 66 1998 471 476
5. E. Gane, and H. Pilmore Management of chronic viral hepatitis before and after renal transplantation Transplantation 74 2002 427 437
6. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
7. J. Rhodes, D.H. Jones, and N.M. Bleehen Increased expression of human monocyte HLA-DR antigens and Fc-gamma receptors in response to human interferon in vivo Clin Exp Immunol 53 1983 739 743
8. F. Fabrizi, G. Lunghi, V. Dixit, and P. Martin Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients Aliment Pharmacol Ther 24 2006 1413 1422
9. S. Baid, N. Tolkoff-Rubin, S. Saidman, R. Chung, W.W. Williams, and H. Auchinloss Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy Am J Transplant 3 2003 74 78
10. M. Durlik, Z. Gaciong, Z. Rancewicz, D. Rowińska, J. Wyzgał, and B. Kozłowska Renal allograft function in patients with chronic viral hepatitis B and C treated with interferon alpha Transplant Proc 27 1995 958 959
11. J.T. Wells, M.R. Lucey, and A. Said Hepatitis C in transplant recipients of solid organs, other than liver Clin Liver Dis 10 2006 901 917
12. G.P. Pageaux, M.N. Hilleret, V. Garrigues, M. Bismuth, H. Audin-Mamlouk, and J.P. Zarski Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study Transpl Int 22 2009 562 567
13. A.A. Aljumah, M.A. Saeed, A.l. Al Flaiw, I.H. Al Traif, A.M. Al Alwan, and S.H. Al Qurashi Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients World J Gastroenterol 18 2012 55 63
14. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guideline for the care of kidney transplant recipients Am J Transplant 9 2009 S1 S155
15. K. Solez, R.B. Colvin, L.C. Racusen, M. Haas, B. Sis, and M. Mengel Banff 07 classification of renal allograft pathology: updates and future directions Am J Transplant 8 2008 753 760
16. B.J. Nankivell, R.J. Borrows, C.L. Fung, P.J. O'Connell, R.D. Allen, and J.R. Chapman The natural history of chronic allograft nephropathy N Engl J Med 349 2003 2326 2333
17. B. Roche, and D. Samuel Hepatitis C virus treatment pre- and post-liver transplantation Liver Int 32 2012 120 128
18. M. Heydtmann, D. Freshwater, T. Dudley, V. Lai, S. Palmer, and S. Hubscher Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation Am J Transplant 6 2006 825 833
19. J.M. Morales, J.M. Campistol, B. Domínguez-Gil, A. Andrés, N. Esforzado, and F. Oppenheimer Long-term experience with kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients Am J Transplant 10 2010 2453 2462
20. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, < http://www.srtr.org/annual-reports/2010/509d-ki.htm >; 2011 [accessed 18th August 2012].
21. M. Berenguer Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin J Hepatol 49 2008 274 287
22. E. Xirouchakis, C. Triantos, P. Manousou, A. Sigalas, V. Calvaruso, and A. Corbani Pegylated interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies J Viral Hepat 15 2008 699 709
23. M. Giusto, M. Rodriguez, L. Navarro, A. Rubin, V. Aguilera, and F. San-Juan Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin Liver Transpl 17 2011 1318 1327
24. H. Hofer, C. Gurguta, U. Bergholz, P. Steindl-Munda, and P. Ferenci Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia Wien Klin Wochenschr 118 2006 595 600